丁苯酞注射液、胶囊序贯疗法辅治急性进展性脑梗死的疗效及其对神经功能的影响

目的 研究丁苯酞注射液、胶囊序贯疗法辅治急性进展性脑梗死（APCI）的临床疗效。方法 选取2018年2月~2019年3月我院收治的APCI患者76例，随机分为对照组和研究组，每组38例。所有患者均接受神经保护、营养支持等常规治疗，对照组给予依达拉奉治疗，研究组给予依达拉奉联合丁苯酞注射液、胶囊序贯疗法治疗，比较两组Bathel指数与NIHSS评分、炎症指标及血液流变学指标。结果 研究组Bathel指数评分高于对照组[（84.22±6.23）分 vs （77.18±5.83）分]，而NIHSS评分低于对照组[（6.77±1.39）分 vs （13.83±2.45）分]，差异具有统计学意义（P＜0.05）。研究组PTX-3、IL-6、TNF-α水平分别为（3.78±1.97）pg/L、（67.11±41.16）ng/L、（14.27±4.01）ng/L，均低于对照组的（5.55±2.33）pg/L、（183.33±45.48）ng/L、（26.53±4.74）ng/L，差异具有统计学意义（P＜0.05）。研究组PSV、LSV、HSV水平分别为（1.04±0.66）mPa·s、（11.48±2.13）mPa·s、（2.92±0.88）mPa·s，均低于对照组的（2.33±1.03）mPa·s、（12.74±2.35）mPa·s、（4.02±1.31）mPa·s，差异具有统计学意义（P＜0.05）。结论 采用依达拉奉联合丁苯酞注射液、胶囊序贯疗法治疗APCI患者，可增强日常活动能力，改善神经功能与炎症反应，有一定的临床应用价值。

Efficacy of Butylphthalide Injection and Capsule Sequential Therapy in the Treatment of Acute Progressive Cerebral Infarction and Its Effect on Neurological Function

Abstract:Objective To study the clinical efficacy of butylphthalide injection and capsule sequential therapy in the treatment of acute progressive cerebral infarction (APCI). Methods 76 patients with APCI admitted to our hospital from February 2018 to March 2019 were randomly divided into the control group and the study group, with 38 cases in each group. All patients received routine treatment such as neuroprotection and nutritional support. The control group received edaravone treatment. The study group received edaravone combined with butylphthalide injection and capsule sequential therapy. The two groups were compared with Bathel index and NIHSS score, inflammation indicators and blood rheology indicators. Results The Bathel index score of the study group was higher than that of the control group [(84.22±6.23) points vs (77.18±5.83) points], and the NIHSS score was lower than the control group [(6.77±1.39) points vs (13.83±2.45) points], the difference was statistical significance (P<0.05). The levels of PTX-3, IL-6 and TNF-α in the study group were (3.78±1.97) pg/L, (67.11±41.16) ng/L, and (14.27±4.01) ng/L, respectively, which were lower than those of the control group (5.55±2.33) pg/L, (183.33±45.48) ng/L, (26.53±4.74) ng/L, the difference was statistically significant (P<0.05). The PSV, LSV, and HSV levels of the study group were (1.04±0.66) mPa·s, (11.48±2.13) mPa·s, and (2.92±0.88) mPa·s, respectively, which were lower than those of the control group (2.33±1.03) mPa·s, (12.74±2.35) mPa·s, (4.02±1.31) mPa·s, the difference was statistically significant (P<0.05). Conclusion The combination of edaravone combined with butylphthalide injection and capsule sequential therapy for APCI patients can enhance daily activities, improve neurological function and inflammatory response, and has certain clinical application value.